Fundz

Alector secures a $1.27 billion deal with Genentech to advance its AL050 Parkinson’s disease program, including $100 million upfront and potential milestones. This partnership extends Alector's cash runway into 2029.

Oct 06, 2026
South San FranciscoBiotechnology

Description

Alector has entered into an exclusive global licensing agreement with Genentech, potentially worth $1.27 billion for its AL050 Parkinson’s disease program. The agreement provides Alector with $100 million upfront, milestone payments up to $1.17 billion, and tiered royalties on net sales. Genentech will manage development, regulatory activities, and commercialization. This strategic partnership extends Alector's cash runway significantly, allowing focus on critical therapeutic advancements.

Company Information

Company

Alector

Location

South San Francisco, California, United States

About

Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease, Parkinson's disease, and frontotemporal dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs.

Related People

Giacomo
Likely contact at this company
••••••••@••••••••

See Giacomo's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Alector's next move

Learn about Strategic plan

Alector signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.